Senix Biotech Registers US Patent for Nanozyme Drug-Based Substance

[Asia Economy Reporter Lee Gwanju] Senics Biotech announced on the 24th that it has completed the registration of U.S. patents for CX111 and CX171, the original base materials of the nanozyme new drug CX213.

CX111 and CX171 are nanozyme therapeutics with indications for subarachnoid hemorrhage and sepsis, respectively.

With this U.S. patent registration, Senics has secured exclusive rights to CX111 and CX171 in the global market, laying the foundation for entry into the global new drug market. The company also plans to continuously build multiple pipelines by improving the efficacy and safety of these base materials.

CX213, which Senics is developing with the goal of the world's first clinical application, is a nanozyme therapeutic with indications for 11 diseases including subarachnoid hemorrhage. In May last year, Senics completed the international patent application PCT (Patent Cooperation Treaty) for the base material patent of CX213. Through a U.S. nanozyme specialized CDMO company, Senics has established a mass production system for CX213 and is accelerating the approval of Phase 1 IND (Investigational New Drug) by conducting non-clinical trials with the global clinical research organization (CRO) Labcorp (formerly COVANCE). Furthermore, the company plans to prepare for designation as an orphan drug, fast track, and breakthrough therapy.

Senics holds two platform technologies, Innosurfis and Iconplex, and four pipelines including CX213. Following a seed investment of 4 billion KRW in July 2019, the company secured a large-scale investment of 18.5 billion KRW in Series A funding in April last year, bringing the total accumulated investment to over 22.5 billion KRW.

This content was produced with the assistance of AI translation services.